Plasmids with bacteriophage Mu sequences receive additional Mu insertions 20-700 times less frequently than plasmids without Mu sequences. The Mu sites required for this transposition immunity were mapped near each end, either of which was sufficient. The left site was between 127 and 203 base pairs from the left end, and the right site was between 22 and 93 base pairs from the right end. These sequences include the innermost but not the outermost of the three binding sites for the Mu A transposition protein at each end of Mu. Transposition immunity was cis-acting and independent of its location on a target plasmid. An additional copy of an immunity site reduced transposition a factor of 10 further. Transposition immunity was seen both during full phage lytic growth, with all the bacteriophage Mu genes, and during normal cellular growth, with a mini-Mu element containing only the Mu c and nerregulatory and A and B transposition genes.
Mu is a temperate bacteriophage that replicates by a process that involves DNA transposition (1) (2) (3) (4) . Upon infection of a susceptible host, Mu DNA can integrate into the host DNA and either establish lysogeny or grow lytically as a phage with hundreds of transposition events. The high frequency with which Mu can transpose has made it a model system for genetic and biochemical analysis.
Transposition of Mu requires both phage-and hostencoded functions. The Mu A transposase protein is absolutely essential for transposition, while the B protein and the arm functions stimulate transposition 100-fold and 10-fold, respectively (5-7). The host-encoded HU protein is also required for the transposition reaction in vitro (8) . Sequences required in cis for Mu transposition are located at both termini, within 163 base pairs (bp) of the left end and 52 bp of the right end (9) . At each end Mu has many repeated sequences, including the terminal 2 bp that are inversely repeated and three nonidentical 30 -bp sequences at each end for binding the Mu A transposase protein (10) . The two Mu ends are not fully equivalent, although Mu elements can transpose at reduced frequencies with two right or two left ends, or with one end and a fortuitous sequence as the other end (11) (12) (13) (14) . Further, in the in vitro system Mu DNA precut at its 3' ends transposes without regard to the ends being on the same molecule, with the right end being used 6 times more frequently than the left end (15) .
Mu transposition in vitro is preferentially directed to plasmids that do not contain Mu sequences (8) . During the course of this work Adzuma and Mizuuchi (16) have shown that this preference does not occur in vitro for the low level of transposition that is found without the Mu B protein, and Mogutov et al. (17) and Reyes et al. (18) have reported that Mu sequences in plasmids reduce the frequency of Mu transposition into those plasmids in vivo. Here we also report this and proceed to map the sites involved to a unique position within each Mu terminal region. We also demonstrate that no later Mu phage products are required.
MATERIALS AND METHODS
Bacterial Strains and Media. Strain MG1655.10 was derived from MG1655 (19) by introducing the recA56 and A(lac} mutations with a series offour P1 transductions. MB1 is a Mu d111678 (ApR) lysogen of MG1655. 10 (20) . Bacteria were grown with Luria-Bertani (LB) or M63 minimal glucose medium (21) . For solid media, 1.5% agar was added. The antibiotic concentrations used were as follows: ampicillin (Ap), 25 ,ug/ml; carbenicillin (Cb), 500 ,ug/ml; chloramphenicol (Cm), 20 tug/ml; kanamycin (Km), 25 ug/ml; streptomycin (Sm), 100 ,ug/ml (for rpsL strains); and tetracycline (Tc), 20 Ag/ml.
General DNA Methods and DNA Sequencing. Plasmid DNA was isolated by a modification of the procedure of Kupersztoch and Helinski (22) . Small-scale plasmid DNA preparations, use of restriction and modifying enzymes, gel electrophoresis, DNA-fragment isolation, and Escherichia coli transformation procedures were carried out according to Maniatis et al. (23) . DNA sequences at deletion endpoints or of Mu end subclones were determined by the dideoxy sequencing procedure (24) using as template either singlestranded DNA from phage M13mpl8 clones (25) or CsClpurified double-stranded plasmid DNA (26) .
Cloning of the Mu Terminal Sequences and Deletion Analysis. The Mu termini were cloned from the pBC177 plasmid, which has the mini-Mu dII4041 (KmR) element inserted in the pUC9 (ApR) plasmid between the Pst I and HindIII sites of the polylinker region with the right terminus oriented proximal to the HindIII site and the lac promoter region (20, 27, 28 Fig. 2 ).
Deletions from the inside into the 117-bp right end of Mu were made from the BamHI site (see Fig. 2 ) of the mini-Mu dII4041 element in pBC4041 (20) . The Fig. 2 ).
Transduction Assay for Immunity (20) . Monomer forms of the ApR and KmR test plasmids were introduced by DNA transformation into the BAC101 and MB1 recA strains lysogenic for Mu d114041 (KmR) and the Mu dII1678 (ApR) mini-Mu and the temperature-sensitive helper phage Mucts. Mu lysates were induced as described (29) and used within a few hours (30) . Infection was carried out by mixing 0.5 ml of a fresh overnight culture of the Mu-lysogenic strain M8820-Mu (20) (20) . Target plasmids derived from pUC9 (ApR) were introduced into cells containing mini-Mu d114041 (KmR) and a complementing Mu helper prophage in the chromosome, both with the temperature-sensitive Mu repressor mutation cts62 (32) . These cells were induced for Mu lytic growth and lysates were prepared. Insertions of the mini-Mu into the plasmid were selected as KmR ApR transductants of a Mu-lysogenic cell. For each case, plasmid DNA from several transductants was examined after restriction endonuclease digestion to verify that insertions of the mini-Mu elements had indeed occurred.
Plasmids containing the terminal 203 bp of the Mu left end, pAD511, and the terminal 117 bp of the Mu right end, pAD500, were found to receive mini-Mu insertions 41 and 250 times less frequently, respectively, than did the pUC9 plasmid or the pUC9-derived control plasmid, pAD520, made by inserting the 350-bp HindIII-BamHI fragment ofpBR322 (33) ( Table 1) .
To show that this phenomenon was not specific to the pUC9 plasmid, a plasmid with a different compatibility group and different drug-resistance genes was used. The Mu right end from plasmid pAD500 was cloned between the HindIII and BamHI sites of pACYC184 (34) . The resulting plasmid, pAD530, received mini-Mu insertions 20 times less frequently than did pACYC184 (Table 1) .
Immunity Is Cis-Acting. The effect of an end of Mu on transposition in trans was tested by using a second plasmid, pACYC184 (CmR), as a transposition target in cells containing pUC9 and the pUC9-Mu right-end clone, pAD500 (Table  1 ). In the presence of the pACYC184 plasmid, the pAD500 Mu right-end clone continued to be immune: it received mini-Mu insertions 117 times less frequently than did pUC9. This immunity did not extend in trans to the pACYC184 plasmid, which did not receive mini-Mu insertions less frequently with the Mu right-end clone pAD500 than with pUC9. Actually, pACYC184 received insertions 22 times more frequently with pAD500 than with pUC9. This may (1988) reflect differences between the pUC9 and pACYC184 plasmids.
Transposition Immunity Can Occur in the Absence of the Mu Late Genes and Mu Lytic Growth. To test for Mu transposition in the absence of Mu lytic growth without the myriad of Mu phage genes, a conjugation assay for transposition was used. Mu d114041 has only the Mu cts62 repressor and ner antirepressor regulatory genes and the A and B transposition genes. An insertion of mini-Mu d114041 into the transmissible F factor pOX38: :minitet (TcR) (31), pAD540, was used as the donor for transposition into pUC9 and the pAD500 and pAD511 clones with the left and right ends of Mu. Selection was for transfer of the ApR marker with the F factor. This transfer is dependent on cointegrate transposition to join the nontransmissible pUC9 plasmids to the transmissible F plasmid.
The presence of the Mu left or right end on pUC9 reduced the frequency of mini-Mu dII4041-mediated cointegration by a factor of 78 and 104, respectively ( Table 2 ). The control plasmid pAD520 did not have a reduction in the frequency of insertion. These data indicate that the Mu functions required for the transposition immunity phenomenon include no more than the Mu regulatory and A and B transposition genes encoded by the mini-Mu element.
Transposition Immunity Is Independent of Position and Increased by Another Copy of a Mu End. The level of immunity was found to be largely independent of the position of the Mu termini within the target plasmid. Approximately the same levels of immunity were seen when the Mu right end was located within the pUC9 polylinker region or at either the single Nde I or the single EcoO109 site. However, the presence of two copies of the Mu right end (pAD504) increased the immunity level 8-16 times over that already observed for the pUC9 clones with one copy of the right end.
Localization of the Mu Immunity Sequences. The sequences on each end of Mu required for transposition immunity were mapped with deletions extending from each side. Deletions on the left end were made by cloning restriction fragments from the 203-bp Mu left-end fragment on pAD511 (see Fig. 2 ). Fig. 1A (open circles) shows that pAD511 resulted in a factor-of-58 reduction in transduction frequency as compared to pUC9. This decrease is approximately the same as the factor-of-41 reduction seen in the experiments of Table 1 . Removal of 77 bp from the inside ofthe left end, leaving only the terminal 126 bp (A513), resulted in the loss ofimmunity. Removal ofan additional 68 bp from the inside, leaving only 58 bp (A&512), resulted in a return ofa small amount ofimmunity (=3-fold). For deletions from the outside of the left-end 203-bp segment (Fig. L4, solid circles) , approximately the same transduction frequency was seen when 58 bp (A514) or 126 bp (A515) were removed. Thus, the 77 bp from 127 to 203 from the left side were sufficient for immunity.
Deletions into the right end were made with BAL-31 exonuclease from inside of Mu starting at bp 117 at the BamHI site on mini-Mu d114041 on plasmid pBC4041 (see Fig. 2) . The frequency at which plasmids with partially deleted Mu ends received mini-Mu dII1678 insertions was Transposition immunity increased slightly when the first 8 bp were removed in A65 and then decreased nearly logarithmically until the last 44 bp remained with A19, which had no significant immunity (Fig. 1B, open circles) . However, the next deletion, A104, which retained the most-terminal 10 bp, actually resulted in an -2-fold increase in the transduction frequency as compared to the A101 deletion of the complete end.
Deletions into the right terminus from the outside were constructed by subcloning various right-end fragments into pUC9 by using the restriction sites indicated in Fig. 2 . The frequency at which these plasmids received mini-Mu dII4041 insertions was measured as the frequency of cotransduction 
DISCUSSION
The sequences required for transposition immunity were mapped to either Mu end. On the left end the immunity site contained only the innermost of the three binding sites for the Mu A protein (10), and on the right side it contained the innermost two of the three binding sites. These sites do not correspond to the strongest or the weakest binding sites, nor do they correspond to the terminal sequences essential for Mu transposition, which include the outer two binding sites (9, 14) . Specifically, on the left side the immunity site was located between bp 127 and bp 203 (Figs. 1A and 2 ), a region that includes the innermost Mu A binding site (L3) and a small part of the next binding site (L2). In contrast, the sequence required for transposition extends from the end to between bp 156 and bp 163, including L1, L2, and part of L3. For partial transposition, at a 15 times lower frequency, the terminal 25 bp with only Li are sufficient (9) . Li and L3 are both strong binding sites, yet only L3 maps in the immunity region. The terminal 58 bp of Mu, however, containing only the Li site, did yield a low (2.3) level of immunity, but this same sequence with additional base pairs up to the terminal 126 bp with Li and part of L2 yielded none. On the right terminus, the immunity sequences were located between bp 1 and bp 93 with deletions from the inside and between bp 21 and bp 117 with deletions from the outside (Figs. 1B and 2 ). The region in common includes the second (R2) and third (R3) Mu A binding sites. The next deletions from the inside, keeping the terminal 75, 63, or 50 bp but missing part or all of R3, had a reduced level of immunity, as did the next deletion from the outside, retaining bp 56 to bp 117 and missing R2 and the first few nonconserved base pairs of R3. Thus, these deletions implicate two nonoverlapping regions, one containing R2 and the other R3, which each yield partial immunity but which together give full immunity. For transposition, only the terminal 52 bp, containing R1 and R2 but not R3, are sufficient, and the terminal 32 bp are sufficient for transposition at a 30 times lower frequency (9) . Only R3 binds Mu A strongly on the right.
Li
As the Mu immunity sites do not correlate with the presence or strength of the A binding sites, they may correlate with another feature or subsequence of the A binding site (14) or with another sequence in this region. An additional sequence in common to the mapped immunity region is a 14-bp stretch of nucleotides located just 5' of the L3 and R3 Mu A binding sites (Fig. 2) that bears some homology to the integration host factor (IHF) binding consensus sequence (35) . These sequences alone, however, do not mediate immunity, since the deletion that removes the outer 61 bp of the Mu right end leaves this sequence and yields a plasmid with no immunity. In addition, a clone of the Mu early operator region known to harbor an IHF binding site, pHKO9 (36), did not confer immunity (data not shown). This clone also has the main Mu operators, and its absence of transposition immunity provides further evidence that the Mu c repressor is not involved.
Our results also indicate that no other Mu genes are needed beyond those encoding the A and B proteins and the repressor (c gene product) and antirepressor (ner gene product) regulatory proteins. These regulatory proteins are probably not involved, since a temperature-sensitive repressor, Mu cts62, was used at the high temperature and neither protein was required in the in vitro system. The in vivo experiments described here are consistent with the early in vitro findings (8, 15) in which mini-Mu transposition preferentially utilized recipient DNA molecules that did not contain mini-Mu insertions. Those in vitro experiments did not use isogenic plasmids, as we have used here, that differ only by the addition of short Mu sequences, since it is known that Mu inserts at different frequencies in different plasmids (see Table 1 ), as well as in different regions of the chromosome (37) and within particular genes (37) (38) (39) (40) .
Recent in vitro experiments (16) (10) , with the thicker black lines marking the 22-bp consensus sequence (9, 14) . Arrows below the sequence indicate the nucleotides removed by the deletions used to localize the immunity sequence. The stippled arrow beneath the Mu sequences at each end denotes nucleotides that bear homology to the IHF binding consensus (35 
